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Giant-cell myocarditis (GCM) is known as a rare, rapidly progressive, and frequently fatal myocardial disease in
young and middle-aged adults. We report about a 76 year old male patient who underwent implantation with a
biventricular Berlin Heart Excor system at the age of 74 due to acute biventricular heart failure caused by giant-cell
myocarditis. The implantation was without any surgical problems; however, a difficulty was the immunosuppressive
therapy after implantation. Meanwhile the patient is 76 years old and lives with circulatory support for about 3 years
without major adverse events. Also, in terms of mobility in old age there are no major limitations. It seems that in
even selected elderly patients an implantation of a long term support with the biventricular Berlin Heart Excor is a
useful therapeutic option with an acceptable outcome.Background
Giant-cell myocarditis (GCM) is known as a rare, rapidly
progressive, and frequently fatal myocardial disease in
young and middle-aged adults. However, few cases have
been reported on GCM in older patients. The paucity of
reported cases on the elderly may reflect less frequent
diagnosis or more or less fulminant course of disease in
this population. Infection, autoimmune processes, and
genetics have all been implicated in the pathogenesis of
this disease, but the etiology is likely to be a complex
multifactorial process. It is attributed to a T lymphocyte-
mediated inflammation of the heart muscle and asso-
ciates with systemic autoimmune diseases in 20% of
cases [1,2]. The most common early manifestations are
heart failure, ventricular arrhythmias, and atrioventricu-
lar block, but GCM may also appear as an acute myo-
cardial infarction and rarely presents as an unexpected
sudden cardiac death. Due to this unspecific clinical
presentation of the patients, which may also be caused
by other heart disease, the diagnosis of GCM fully de-
pends on microscopy of the heart muscle with a sensitivity* Correspondence: Christian.bireta@med.uni-goettingen.de
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unless otherwise stated.of 80% to 85% [1,2]. The histological hallmark of GCM is
a multifocal inflammatory infiltrate manifested by many
multinucleated giant cells and by extensive myocardial cell
necrosis in the absence of granuloma formation [3]. Be-
cause of possible life threatening complications associated
with GCM and the potential for benefit from treatment,
early biopsy is recommended. An early diagnosis of GCM
is crucial. Also, apart from standard heart failure therapy
and physical rest a tailored immunosuppressive treatment
may significantly alter the clinical course of the patients.
The prognosis of patients with GCM is poor, and the
probability of death or transplantation at 1 year from on-
set of symptoms is high [1,2]. Even after transplantation,
there is a 20-25% GCM recurrence in the transplanted
heart [4].Case presentation
A 74 year-old man was transferred to our institution
with biventricular heart failure and suspected myocardi-
tis. One week earlier, he was admitted to a local hospital
due to decreased exercise tolerance and a rapidly worsen-
ing shortness of breath. Three weeks before, he had flu-
like syndrome. Due to coronary heart disease the patient
had undergone a coronary artery bypass grafting 20 yearshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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giogram showed that all bypass-grafts were competent.
On admission, his physical examination was unremark-
able except for tachycardia and dyspnea. ECG revealed a
sinus rhythm with a heart rate of approximately 120 bpm
without significant repolarisation disturbances. Transtho-
racic echocardiography showed an increased left ventricu-
lar (LV) and-diastolic dimension of 58 mm with global
thickening and severely reduced systolic function (ejection
fraction 15%). No new regional wall abnormalities were
noted. Chest X-ray showed a cardiomegaly and pleural
effusion on the left side. Blood chemistry showed a
slightly increased troponin T and creatine kinase isoen-
zyme MB. NT-pro brain natriuretic peptide (BNP) level
was 18186 ng/L. Serologic tests for cardiotropic viruses
were negative. The patient was transferred to the car-
diac intensive care unit, and standard heart failure therapy
was started including beta-blocker, diuretics, and angio-
tensin converting enzyme. Four days later, the patient had
a clinical deterioration with worsening of dyspnea and se-
vere hypotension and was stabilized by inotropic support
including levosimendan therapy. Because of developing
hemodynamic instability one day later with signs of pul-
monary edema and catecholamine refractory cardiogenic
shock a femoral veno-arterial extracorporeal membrane
oxygenation (ECMO) was initiated to stabilize the patient
and as bridge to decision. On the next day, endomyocar-
dial biopsies were taken from the right ventricle (septum).
Histological study revealed acute GCM with extensive
myocardial cell necrosis and inflammatory cell infiltrates.
Due to the poor prognosis of GCM, no improvement in
biventricular function and no option for cardiac trans-
plantation a biventricular Berlin Heart Excor system
(BIVAD) was implanted on day 5 via ECMO support.
In addition, the patient was started on double immuno-
suppressive therapy that included prednisolone and
cyclosporine. Due to an infection of the left ventricular
cannula (Staphylococcus aureus and Pseudomonas aer-
uginosa) the immunosuppressive therapy was stopped
two month after implantation. The infection was suc-
cessfully treated with antibiotics according the microbi-
ologists recommendation. After a hospital stay of three
months the patient is meanwhile 76 years old and lives
with circulatory support for about 3 years with no
problems and without major adverse events. The latest
echocardiography showed still a biventricular failure.
In terms of mobility in old age there are no major
limitations.
Discussion
Giant-cell myocarditis is known as a rare, rapidly pro-
gressive, and frequently fatal myocardial disease in
young and middle-aged adults. However, few cases have
been reported in older patients. GCM has multiplecauses and the etiology is likely to be a complex multi-
factorial process which is attributed to T lymphocyte-
mediated inflammation of myocardium. The prognosis
of patients with GCM is poor and the probability of
death or transplantation is high. Apart from standard
heart failure therapy a tailored immunosuppressive treat-
ment may significantly alter the clinical course of the pa-
tients [1,2]. A recent work from Kandolin et al. shows that
combined immunosuppression may lead to a partial re-
mission characterized by freedom from severe heart fail-
ure and better estimated transplant-free survival [5].
Mechanical circulatory support with intra-aortic balloon
pump, ECMO, and ventricular assist device (VAD) ther-
apy have all been used in GCM patients as bridge to trans-
plantation or occasional recovery [1,6]. As in our case
transplantation was not possible due to the high age of the
patient. The only therapeutic option was implantation
of a BIVAD. Critical circulatory status, previous cardiac
operations, older age and associated multimorbidity are
the key determinants rendering the conditions of per-
manent mechanical circulatory support (MCS) in pa-
tients of advanced age and are associated with a high
postoperative mortality in this cohort [7]. Optimal pa-
tient selection and timing of MCS implantation are
closely related to ethical issues. There is still a question
based on which criteria can we predict the clinical course
and when are we allowed to decide about the restriction
of access to MCS in severely ill patients with limited prog-
nosis. In our opinion, as well as by others, because of
the high early mortality, the inclusion of patients with
the combination of advanced age and profound ECMO
implantation and all measurable values (e.g. creatinine,
urea liver enzymes) were within normal range. He did
not require dialysis and had no need for re-exploration
for bleeding. And thirdly, he was neurologically alert
responsive straight after ECMO implantation and ex-
pressed the wish for a BIVAD implantation after diagno-
sis assurance. We choose the Berlin Heart Excor system
for some reasons. There is a huge experience with this
system worldwide even in elderly patients. Also, long-
term surviving patients with the Berlin Heart Excor re-
quired exceptionally few hospital readmissions resulting
in a long out-of-hospital VAD support time. And finally
the EXCOR® Adult is intended for use in acute or chro-
nic ventricular failure refractory to optimal medical and
interventional therapy especially for biventricular heart
failure. Our patient is meanwhile 76 years old and lives
with circulatory support for about 3 years with no major
problems and without major adverse events.Conclusions
Even in selected elderly patients an implantation and
long term support with the biventricular Berlin Heart
Bireta et al. Journal of Cardiothoracic Surgery  (2015) 10:14 Page 3 of 3Excor may useful as therapeutic option with an accept-
able outcome.
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